Sharemaestro Newsreel

Realty Income (O) Stock Looks Fully Priced Despite Its 31% Three Year Gain

Realty Income has delivered a 3 year share price gain that many income investors would happily take, even though the stock has been under pressure in recent months. Given that backdrop and several new partnerships in play, the key issue now is whether today's …

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from …

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)' 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker's board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped …

Baird Adjusts Price Target on Realty Income to $59 From $65, Keeps Neutral Rating

Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology …

How to Build $11,400 a Month in Dividend Income From Four Income Buckets

Is Realty Income's Nearly 6% Yield a Bargain or a Trap?

Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

Novartis AG's (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca's …

European Markets Close Lower in Thursday Trading as Bond Yields, Oil Prices Rise

The European stock markets closed lower in Thursday trading as bond yields and oil prices surged whi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

Realty Income vs. Prologis: Which REIT Has the Winning Edge?

Realty Income Corporation O and Prologis, Inc. PLD are both large, investment-grade REITs built around recurring real estate cash flows, broad tenant relationships and access to multiple sources of capital. Both are also expanding beyond their traditional property lanes, using scale to pursue private-capital …

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?

Vertex Pharmaceuticals Incorporated VRTX has established a dominant position in the cystic fibrosis (CF) market through its portfolio of CFTR modulators, including Trikafta/Kaftrio and the newer Alyftrek. Vertex's marketed CF therapies are currently used by nearly three-quarters of the approximately 97,000 people with CF …

Realty Income Corporation (O) Is a Trending Stock: Facts to Know Before Betting on It

Realty Income Corp. (O) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this real …

Mercialys Appoints Jérôme Engelbrecht as Group CFO

PARIS, September 24, 2026--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY) announces the appointment of Jérôme Engelbrecht as Group CFO and member of the Executive Committee, effective September 1, 2026. In this role, Jérôme Engelbrecht oversees all Finance functions as well as Investor Relations at Mercialys, and …

Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis

Company Logo The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CAGR. Growth is driven by rising chronic disease prevalence, biologics, biosimilars, advanced therapies, self-administration and connected drug-device …

Realty Income Shares Fall After Scotiabank Downgrade

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about 1.0% to …

How to Build $5,350 a Month in Tax-Free Dividend Income Inside a Roth IRA

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis Pharmaceuticals IONS announced positive results from two partnered programs, both of which are in phase III development. IONS Secures Phase III Win in ALS The first study, called FUSION, evaluated ulefnersen for the treatment of patients with amyotrophic lateral sclerosis (ALS) caused by …

Is Realty Income (O) Cheap After Its New Europe Venture And Recent Slide?

Realty Income (O) has established a new euro joint venture with KKR, contributing 54 European net lease properties, and is also preparing to speak at BofA's NY Global Real Estate Conference. Realty Income's share price has drifted lower recently, with a 1-month share price …

Scotiabank Downgrades Realty Income to Sector Perform From Sector Outperform, Adjusts Price Target to $59 From $67

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAutologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem …

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. …

Own Realty Income By Sept. 30 to Qualify for Its Oct. 15 Dividend. Here's How Many Shares You'd Need for $1,251 in Yearly Dividends.

Realty Income (O) Forms European Net Lease Joint Venture

Realty Income (NYSE:O) agreed a large euro-denominated joint venture with KKR for European net lease assets. The partnership covers a diversified pool of assets across four European countries with a substantial committed capital inflow. The JV structure introduces KKR as a long term capital …

3 Integrated Oil And Gas Stocks Tied To Iran Supply Risk

Geopolitics around Iran have moved from background noise to front-page risk, and that shift is rippling through global integrated oil and gas producers. When conflict risk, energy supply questions and election politics collide, pricing for crude and related stocks can swing hard, creating both …

Realty Income Has Outperformed the S&P 500 in 11 of 13 Stock Market Corrections Since 1994. Here's Why I'd Hold It Forever.

Since Realty Income's (NYSE:O) public market listing in 1994, the stock market has endured 13 sell-offs of 10% or more. The real estate investment trust (REIT) has outperformed the market in 11 of those corrections. Its average decline during these sell-offs is only 2.6%, …

How Long Does It Take to Build $1,600 a Month in Dividend Income on $1,000 a Month in Savings?

Quick Read A blended portfolio of 40% SCHD, 20% DGRO, 25% JEPI, and 15% O produces a 4.7% blended yield, requiring roughly $411,000 in capital for $1,600 monthly income. Reinvesting dividends cuts the timeline from 34 years to about 20 years at 4.7%, or …

How Large Does Your Portfolio Need to Be to Generate $9,300 a Month From Three Income Buckets?

Quick Read Generating $9,300 a month ($111,600/year) requires $3.19M at a conservative 3.5% yield, but a blended three-bucket portfolio at 7% cuts that to $1.67M. High-yield assets like GBDC (11.5% yield) can slash capital needs to $1M, but distribution cuts and NAV erosion are …

Realty Income Falls for 3 Months: Two Wall Street Pros Say Near 30% Gains Lie Ahead for the Dividend Powerhouse.

Quick Read Realty Income (O) trades 27% below Spector and Goldsmith's $72 Street-high target while paying a 5.6% yield backed by 670+ consecutive monthly dividends. Agree Realty (ADC) leads net-lease peers in consensus implied upside, but Realty Income's $72 Street-high target surpasses every peer's …

Creatio Invests $300 Million in Its Bank.AI Platform to Drive AI Adoption in Financial Services

BOSTON, Sept. 22, 2026 /PRNewswire/ -- Creatio, an AI CRM and workflow platform where people and AI agents work together, today announced a $300 million investment from 2026 through 2028 in Creatio Bank.AI, its market-leading offering for banks and financial institutions. The investment comes …

Spain Heatwave Puts Solaria Stock In Focus For Climate Adaptation Investors

Spain's record heat, wildfires, and drought are no longer distant headlines. They are starting to reshape where capital feels safe and where it looks more exposed. That shift creates a live question for your portfolio: Which Spanish stocks could benefit from climate adaptation spending, …

Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First

Company Logo Orphan drug demand is rising as genomics, biologics and personalized therapies advance, aided by faster approvals, government incentives, advocacy and improved rare-disease diagnosis. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's …

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global license agreement with Novartis Pharma AG ("Novartis") …